Creative Commons source reading · Neuromuscular and peripheral nerve disorders
Neuroinflammatory Process Involved in Different Preclinical Models of Chemotherapy-Induced Peripheral Neuropathy.
Giulia Fumagalli; Laura Monza; Guido Cavaletti; Roberta Rigolio; Cristina Meregalli
Originally published in Frontiers in immunology · 2021-02-04
From the article
Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.
Abstract
Peripheral neuropathies are characterized by nerves damage and axonal loss, and they could be classified in hereditary or acquired forms. Acquired peripheral neuropathies are associated with several causes, including toxic agent exposure, among which the antineoplastic compounds are responsible for the so called Chemotherapy-Induced Peripheral Neuropathy (CIPN). Several clinical features are related to the use of anticancer drugs which exert their action by affecting different mechanisms and structures of the peripheral nervous system: the axons (axonopathy) or the dorsal root ganglia (DRG) neurons cell body (neuronopathy/ganglionopathy). In addition, antineoplastic treatments may affect the blood brain barrier integrity, leading to cognitive impairment that may be severe and long-lasting. CIPN may affect patient quality of life leading to modification or discontinuation of the anticancer therapy. Although the mechanisms of the damage are not completely understood, several hypotheses have been proposed, among which neuroinflammation is now emerging to be relevant in CIPN pathophysiology.
Discussion
Chemotherapy represents the only available approach for fighting many different cancer types. However, this regimen is often associated with CIPN onset that frequently results in premature interruption of the treatment. Despite the recent development of some symptoms-related therapies for CIPN, no preventive or curative interventions are available. The mechanisms underlying CIPN are complex and not fully elucidated.
Editorial reading guide
- Which patient population and reference standard did the authors use?
- Was the finding validated in a separate cohort, and how might patient selection affect it?
